Page 1848 - Hematology_ Basic Principles and Practice ( PDFDrive )

1644 Part X Transplantation

TABLE Comparison of Double-Unit Cord Blood Transplantation With Adult Donor HSC Transplantation—cont’d
107.3
CI (%) of
Neutrophil
Engraftment
Age Days to
Median Neutrophil III–IV
Graft (range), in Conditioning Engraftment, II–IV Acute Acute Chronic
Reference (Patients n) years (Patients n) Median (range) GVHD GVHD GVHD TRM Relapse Survival
Brunstein 121 CBT 55 Flu/Cy/TBI 9 days 50% 17% 34% at 2 19% at 2 49% at 2 2-year LFS:
et al 90 (23–68) 83% at day years years years 31%
+28 2-year OS:
93% at day 37%
+42
40 CBT 48 Other 20 days 33% 18% 36% at 2 52% at 2 35% at 2 2-year LFS:
(21–67) 83% at day years years years 15%
+28 2-year OS:
92% at day 19%
+42
313 59 Other 13 days 93% 33% 14% 56% at 2 21% at 2 44% at 2 2-year LFS:
8/8- (23–69) at day +28 years years years 35%
PBPC 98% at day 2-year OS:
+42 44%
111 58 Other 12 days 40% 23% 54% at 2 28% at 2 44% at 2 2-year LFS:
7/8- (21–69) 92% at day years years years 29%
PBPC +28 2-year OS:
96% at day 37%
+42
Chen et 64 CBT 53 RIC 21.5 (13–70) 14.1% 3.1% 21.9% at 26.9% at 2 42.7% at 3 OS: 46% at
al 91 (19–67) ATG 99% days 2-years years years 3 years
85.9% by day PFS: 30% at
+50 3 years
221 URD 58 RIC 13 (2–181) 20.3% 6.8% 53.9% at 10.4% at 49.8% at 3 OS: 50% at
(97% PB) (19–73) ATG 0% days 2-years 2-years years 3 years
98.6% by day PFS: 40% at
+50 3 years
Jacobson 42 CBT 49 Flu/Mel based 21.5 (13–107) 21% 24% 11% at 2 40% at 2 PFS: 49% at
et al 86 (20–67) ATG (100%) years years 2 years
OS: 66% at
2 years
102 56 Bu/Flu based 12% 54% 11% at 2 32% at 2 PFS: 57% at
PB–MUD (20–73) ATG 0% years years 2 years
PFS: 68% at
2 years
Robin et 129 CBT 57 RIC 20 (6–72) 31% 23% at 2 42% at 2 30% PFS: 28% at
al 92 (20–72) In-vivo days years years 2 years
T-depletion 78% OS: 30% at
(40%) 2 years
502 60 RIC 16 (3-60) days 29% – 41% at 2 31% at 2 25% PFS: 44% at
PB–MUD (20–76) In vivo 98% years years 2 years
T-depletion OS: 49% at
(83%) 2 years
379 10/10 60 RIC – – – 35% at 2 32% at 2 23% PFS: 50% at
PB (24–76) In vivo years years 2 years
T-depletion OS: 45% at
(82%) 2 years
107 9/10 61 RIC – – – 44% at 2 36% at 2 28% PFS: 36% at
PB (20–74) In vivo years years 2 years
T-depletion OS: 43% at
(87%) 2 years
Rodrigues 104 CBT 48 RIC 81% at day 29% at 3 26% at 3 29% at 3 41% at 3 OS: 56% at
et al 93 (18–67) ATG/ALG/ +60 years years years years 3 years
Alemtuzumab
(21%)
541 MUD 50 RIC 95% at day 32% at 3 52% at 3 28% at 3 36% at 3 OS: 49% at
(18–70) ATG/ALG/ +60 years years years years 3 years
Alemtuzumab
(73%)